Follow
Tyler Beyett
Tyler Beyett
Assistant Professor of Pharmacology and Chemical Biology, Emory University
Verified email at emory.edu
Title
Cited by
Cited by
Year
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer
C To, TS Beyett, J Jang, WW Feng, M Bahcall, HM Haikala, BH Shin, ...
Nature cancer 3 (4), 402-417, 2022
692022
Carboxylic acid derivatives of amlexanox display enhanced potency toward TBK1 and IKKε and reveal mechanisms for selective inhibition
TS Beyett, X Gan, SM Reilly, L Chang, AV Gomez, AR Saltiel, ...
Molecular pharmacology 94 (4), 1210-1219, 2018
392018
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors
TS Beyett, C To, DE Heppner, JK Rana, AM Schmoker, J Jang, ...
Nature communications 13 (1), 2530, 2022
382022
Design, synthesis, and biological activity of substituted 2-amino-5-oxo-5H-chromeno [2, 3-b] pyridine-3-carboxylic acid derivatives as inhibitors of the inflammatory kinases …
TS Beyett, X Gan, SM Reilly, AV Gomez, L Chang, JJG Tesmer, AR Saltiel, ...
Bioorganic & medicinal chemistry 26 (20), 5443-5461, 2018
312018
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer
IT Nakamura, S Kohsaka, M Ikegami, H Ikeuchi, T Ueno, K Li, TS Beyett, ...
npj Precision Oncology 5 (1), 66, 2021
242021
Navigating the conformational landscape of G protein–coupled receptor kinases during allosteric activation
XQ Yao, MC Cato, E Labudde, TS Beyett, JJG Tesmer, BJ Grant
Journal of Biological Chemistry 292 (39), 16032-16043, 2017
232017
Perturbation of the interactions of calmodulin with GRK5 using a natural product chemical probe
TS Beyett, AE Fraley, E Labudde, D Patra, RC Coleman, A Eguchi, ...
Proceedings of the National Academy of Sciences 116 (32), 15895-15900, 2019
222019
A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non–Small Cell Lung Cancer
J Son, J Jang, TS Beyett, Y Eum, HM Haikala, A Verano, M Lin, ...
Cancer research 82 (8), 1633-1645, 2022
202022
Design of a “two-in-one” mutant-selective epidermal growth factor receptor inhibitor that spans the orthosteric and allosteric sites
F Wittlinger, DE Heppner, C To, M Günther, BH Shin, JK Rana, ...
Journal of medicinal chemistry 65 (2), 1370-1383, 2021
182021
Structural basis for inhibition of mutant EGFR with lazertinib (YH25448)
DE Heppner, F Wittlinger, TS Beyett, T Shaurova, DA Urul, B Buckley, ...
ACS medicinal chemistry letters 13 (12), 1856-1863, 2022
132022
Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC
TW Gero, DE Heppner, TS Beyett, C To, SC Azevedo, J Jang, T Bunnell, ...
Bioorganic & medicinal chemistry letters 68, 128718, 2022
102022
Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib
E Tkacik, K Li, G Gonzalez-Del Pino, BH Ha, J Vinals, E Park, TS Beyett, ...
Journal of Biological Chemistry 299 (5), 2023
82023
Macrocyclization of quinazoline-based EGFR inhibitors leads to exclusive mutant selectivity for EGFR L858R and Del19
JA Amrhein, TS Beyett, WW Feng, A Krämer, J Weckesser, IK Schaeffner, ...
Journal of medicinal chemistry 65 (23), 15679-15697, 2022
82022
Biochemical characterization of the interaction between KRAS and Argonaute 2
JJ Waninger, TS Beyett, VV Gadkari, RF Siebenaler, C Kenum, S Shankar, ...
Biochemistry and Biophysics Reports 29, 101191, 2022
72022
Characterization of a hyperphosphorylated variant of G protein-coupled receptor kinase 5 expressed in E. coli
TS Beyett, Q Chen, EJ Labudde, J Krampen, PV Sharma, JJG Tesmer
Protein expression and purification 168, 105547, 2020
42020
Oncogenic K-Ras suppresses global miRNA function
B Shui, TS Beyett, Z Chen, X Li, G La Rocca, WM Gazlay, MJ Eck, KS Lau, ...
Molecular Cell 83 (14), 2509-2523. e13, 2023
32023
Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors.
T Damghani, F Wittlinger, TS Beyett, MJ Eck, SA Laufer, DE Heppner
32023
Examining molecular factors of inactive versus active bivalent EGFR inhibitors: A missing link in fragment-based drug design.
F Wittlinger, BC Ogboo, CD Pham, IK Schaeffner, SP Chitnis, T Damghani, ...
32023
Synthesis of deuterium‐labelled amlexanox and its metabolic stability against mouse, rat, and human microsomes
X Gan, MW Wilson, TS Beyett, B Wen, D Sun, SD Larsen, JJG Tesmer, ...
Journal of Labelled Compounds and Radiopharmaceuticals 62 (5), 202-208, 2019
32019
Molecular basis for targeting, inhibition, and receptor phosphorylation in the G protein-coupled receptor kinase 4 subfamily
TS Beyett, SJ Bandekar, JJG Tesmer
G Protein-Coupled Receptor Kinases, 59-74, 2016
32016
The system can't perform the operation now. Try again later.
Articles 1–20